ONESOURCEBSEOnesource Specialty Pharma LtdMediumNeutral
Announced Wed, 13 May · 13:35 IST

Update on Composite Scheme of Arrangement and Amalgamation (Merger by Absorption) amongst Steriscience Specialities Private Limited, Brooks Steriscience Limited, Steriscience Pte. Limited, ....

Deal CancelledStrategic Transactions View source PDF

ONESOURCE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-0.8%1-day move
₹1830.10
prior close
₹1752.10
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.1+0.3+1.5+1.3-0.8+0.2-1.1+1.1+2.4-0.3-0.3-11.4-8.6
Up moveDown movePending
AI summary

Onesource Specialty Pharma's Board has decided not to proceed with the proposed merger by absorption involving Steriscience Specialties, Brooks Steriscience, Steriscience Pte, and Strides Pharma Services. The scheme, which was meant to bring SteriScience's Poland and Baroda facilities into OneSource, received in-principle approval earlier on February 26, 2026. Citing stakeholder interests, the Board has halted the transaction in its current form. The companies plan to revisit the deal only after successfully delivering their FY28 financial guidance.

Likely market impact

The scrapped merger removes near-term consolidation upside for Onesource shareholders. The decision signals a pivot to prioritising financial targets over expansion, which may impact near-term growth expectations for the stock.